Armata Pharmaceuticals, Inc.
(NYSE Amex Equities : ARMP)

( )
ARMP After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
26.11%281.871.4%$749.34m
AMGNAmgen, Inc.
0.94%204.831.3%$389.48m
CELGCelgene Corp.
1.26%104.701.3%$375.89m
GILDGilead Sciences, Inc.
1.00%65.861.0%$371.46m
ILMNIllumina, Inc.
-1.52%309.053.5%$230.08m
VRTXVertex Pharmaceuticals, Inc.
4.10%191.061.9%$217.62m
REGNRegeneron Pharmaceuticals, Inc.
1.11%301.312.6%$207.80m
EXASEXACT Sciences Corp.
-4.25%88.8524.0%$175.92m
ALXNAlexion Pharmaceuticals, Inc.
-1.44%99.281.9%$169.24m
AAgilent Technologies, Inc.
-1.05%74.691.6%$132.10m
SGENSeattle Genetics, Inc.
-2.23%98.646.2%$130.55m
SRPTSarepta Therapeutics, Inc.
-1.24%85.5514.6%$127.16m
BMRNBioMarin Pharmaceutical, Inc.
-1.01%67.734.3%$95.03m
ALDRAlder Biopharmaceuticals, Inc.
-0.21%18.8810.2%$94.86m
NKTRNektar Therapeutics
-2.99%17.205.5%$82.10m

Company Profile

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains. The company was founded on May 9, 2019 and is headquartered in Los Angeles, CA.